AUM Pharmacy
Health Hub
Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
slide-0
slide-1
slide-2
slide-3
slide-4

Siglinu M 50/500 Tablet

Prescription Icon
Prescription Required

Marketer

Inuen Healthcare Pvt Ltd

Salt Composition

Sitagliptin (50mg) + Metformin (500mg)

Overview Siglinu M 50/500 Tablet

Combiflex DM 50/500 tablets combine two medications to manage elevated blood glucose in type 2 diabetes. This dual action helps prevent serious diabetic complications like kidney disease and vision loss, potentially lowering heart attack and stroke risks. Combiflex DM 50/500 may be used alone or with other diabetes treatments, and is most effective when coupled with a balanced diet and regular physical activity. Dosage is tailored to your individual health status, blood sugar readings, and other medications. Consuming it with food minimizes stomach upset. Consistent daily use, at the same time each day, maximizes effectiveness; discontinue only as directed by your physician. Adherence to your doctor's recommended diet and exercise plan is crucial. Lifestyle significantly impacts diabetes management. Common side effects include diarrhea, nausea, vomiting, indigestion, headache, and throat irritation. Low blood sugar (hypoglycemia) is a potential side effect, especially when used with insulin or sulfonylureas; learn how to identify and address this. This medication isn't for everyone. Inform your doctor of any history of kidney, liver, or heart conditions, pancreatic issues, or excessive alcohol consumption before starting treatment. Pregnant or nursing individuals must consult their doctor. Interactions with other medications are possible; disclose all medications to ensure safety. Alcohol should be avoided due to its blood glucose-lowering effect. Your doctor will monitor your kidney function and blood sugar levels throughout treatment.

Uses of Siglinu M 50/500 Tablet

Managing type 2 diabetes

Major Benefits of Siglinu M 50/500 Tablet:

Consume this medication precisely as your physician directs, adhering to both the prescribed dosage and treatment period. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. It's recommended to take Siglinu M 50/500 Tablet with food.

Common Side effects of Siglinu M 50/500 Tablet:

  • Decreased appetite
  • Vomiting
  • Upper respiratory tract infection
  • Hypoglycemia (low blood glucose level)
  • Abdominal bloating
  • Nausea
  • Diarrhea

How to use Siglinu M 50/500 Tablet:

Consume this medication precisely as directed by your physician, adhering to the prescribed dosage and treatment period. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. It's recommended to take Siglinu M 50/500 Tablet with a meal.

How Siglinu M 50/500 Tablet works:

Siglinu M 50/500 tablets contain sitagliptin and metformin, working synergistically to manage blood glucose. Sitagliptin enhances insulin production by the pancreas, improves insulin utilization, and decreases hepatic glucose output. Metformin, a biguanide, reduces liver glucose production, slows intestinal glucose absorption, and enhances insulin sensitivity. This dual action leads to improved glycemic control.

SAFETY ADVICE

AlcoholAlcoholUNSAFE

Combining Siglinu M 50/500 Tablet with alcohol is not advisable.

PregnancyPregnancyCONSULT YOUR DOCTOR

The use of Siglinu M 50/500 Tablet during pregnancy may pose risks. While human data is scarce, animal research indicates potential harm to a fetus. A physician will assess the advantages against possible dangers prior to prescribing. Physician consultation is recommended.

Breast feedingBreast feedingCONSULT YOUR DOCTOR

Lactation and Siglinu M 50/500 Tablet use are likely incompatible. Available human data indicate potential transfer to breast milk, posing a risk to the infant.

DrivingDrivingCAUTION

Driving ability can be impaired by both hypoglycemia and hyperglycemia. Refrain from driving if you experience these conditions.

KidneyKidneyCAUTION

Patients with kidney impairment should use Siglinu M 50/500 Tablets cautiously, potentially requiring dosage modification. Consult a physician for guidance. Siglinu M 50/500 Tablets are contraindicated in patients with severe kidney disease. Close monitoring of renal function is recommended during treatment.

LiverLiverUNSAFE

Patients with liver conditions should likely refrain from using Siglinu M 50/500 Tablets due to potential safety concerns. A physician's consultation is recommended.

What if you forget to take Siglinu M 50/500 Tablet :

Should you forget a Siglinu M 50/500 Tablet dose, administer it promptly. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.

Facts to Know About Siglinu M 50/500 Tablet

LabelValue
Developing Habits No.
Treatment Category Diabetes Management

FAQs on Siglinu M 50/500 Tablet

Siglinu M 50/500 Tablet combines sitagliptin and metformin to treat type 2 diabetes in adults. This combination improves blood sugar control when used with diet and exercise. Metformin reduces liver glucose production and enhances insulin sensitivity, while sitagliptin increases insulin release by inhibiting DPP-4. It's not suitable for individuals under 18.
Prolonged use of Siglinu M 50/500 Tablets can lead to vitamin B12 deficiency by hindering its absorption in the stomach. This deficiency may cause anemia, nerve damage (manifesting as numbness, tingling in extremities, weakness, and balance problems), and urinary issues, potentially affecting mental state. To mitigate this risk, annual supplemental vitamin B12 is recommended by some researchers.
Siglinu M 50/500 Tablet may cause common side effects such as low blood sugar (hypoglycemia), taste changes, nausea, stomach pain, diarrhea, headache, and upper respiratory infections. Rare but serious side effects include lactic acidosis. Prolonged use may also result in vitamin B12 deficiency.
Siglinu M 50/500 Tablets are contraindicated in patients with known allergies to its components or excipients, and those with severe kidney or liver impairment, congestive heart failure, lactic acidosis, or diabetic ketoacidosis.
Combining alcohol and Siglinu M 50/500 Tablets is unsafe due to the increased risk of lactic acidosis.
Store this medication in its original, tightly closed container, as directed on the label or packaging. Discard any unused medication and keep it out of reach of children, pets, and others.
Yes, Sitagliptin + Metformin (like Siglinu M 50/500 Tablet) can cause lactic acidosis, a serious medical emergency resulting from excessive blood lactic acid (also known as Metformin-associated lactic acidosis or MALA). This rare side effect is more likely in patients with kidney disease, older adults, or those who consume significant amounts of alcohol. Symptoms include muscle pain or weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal pain, and slow heart rate. If you experience these, discontinue Sitagliptin + Metformin and seek immediate medical attention.
Siglinu M 50/500 Tablet combines sitagliptin and metformin to manage type 2 diabetes in adults. It helps control blood sugar when used with diet and exercise. Metformin reduces liver glucose production and improves insulin sensitivity, while sitagliptin boosts insulin release by inhibiting DPP-4. This medication is not suitable for individuals under 18.
Siglinu M 50/500 Tablet may cause common side effects such as low blood sugar (hypoglycemia), taste changes, nausea, stomach pain, diarrhea, headache, and upper respiratory infections. Rare but serious side effects include lactic acidosis. Prolonged use can also result in vitamin B12 deficiency.
Patients with known allergies to Siglinu M 50/500 Tablet components or excipients, or those with severe kidney or liver impairment, congestive heart failure, lactic acidosis, or diabetic ketoacidosis should not use this medication.
Combining Siglinu M 50/500 Tablet with alcohol is unsafe and may heighten the risk of lactic acidosis.
Yes, Siglinu M 50/500 Tablet can cause lactic acidosis, a serious medical emergency resulting from excessive blood lactic acid (also known as Metformin-associated lactic acidosis or MALA). This rare side effect is a reason to avoid metformin in patients with kidney disease, the elderly, or those who consume large amounts of alcohol. Symptoms may include muscle pain or weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal pain, and bradycardia. If you experience these, discontinue Sitagliptin + Metformin and seek immediate medical attention.
Prolonged Siglinu M 50/500 Tablet use can lead to vitamin B12 deficiency by hindering its absorption. This deficiency, if left untreated, may cause anemia, nerve damage (manifesting as tingling, numbness in extremities, weakness, and balance problems), urinary issues, and cognitive changes. To mitigate this risk, annual supplemental vitamin B12 is recommended by some researchers.
Store this medication in its original, tightly closed container, following the storage instructions on the label. Discard any unused medication and keep it out of reach of children, pets, and others.
Siglinu M 50/500 Tablet combines sitagliptin and metformin to manage type 2 diabetes in adults. This combination improves blood sugar control when used with diet and exercise. Metformin reduces liver glucose production and enhances insulin sensitivity, while sitagliptin increases insulin release by inhibiting DPP-4. This medication is not suitable for individuals under 18.
Siglinu M 50/500 Tablet may cause common side effects such as hypoglycemia, taste changes, nausea, stomach pain, diarrhea, headache, and upper respiratory infections. Rare but serious side effects include lactic acidosis. Prolonged use can also result in vitamin B12 deficiency.
Siglinu M 50/500 Tablets are contraindicated in patients with known allergies to its components or excipients, and in those with severe kidney or liver impairment, congestive heart failure, lactic acidosis, or diabetic ketoacidosis.
Combining alcohol and Siglinu M 50/500 tablets is unsafe and may heighten the risk of lactic acidosis.
Sitagliptin/Metformin (like Siglinu M 50/500) can cause lactic acidosis, a serious medical emergency involving high blood lactic acid levels (also known as MALA – Metformin-associated lactic acidosis). This rare side effect necessitates avoiding this medication in patients with kidney disease, the elderly, or those who consume excessive alcohol. Symptoms include muscle pain/weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal pain, and bradycardia. If you experience these, discontinue Sitagliptin/Metformin and seek immediate medical attention.
Prolonged Siglinu M 50/500 Tablet use can lead to vitamin B12 deficiency by hindering its absorption. This deficiency may cause anemia, nerve damage (manifesting as numbness, tingling in extremities, weakness, and balance problems), and urinary or cognitive issues. To mitigate these risks, annual supplemental vitamin B12 is recommended by some researchers.
Store this medication in its original, tightly closed container as directed on the label or packaging. Discard any unused medication and keep it out of reach of children, pets, and others.
Siglinu M 50/500 Tablet
151